protein

Recombinant human alpha-Synuclein (A53T) protein

SNA2002

20 ug

55 USD

Recombinant human alpha-Synuclein (A53T) protein

1-140aa

SNA2002

NP_000336.1

A Parkinson's disease-related point mutant (A53T) of alpha-synuclein. A53T mutant of alpha-synuclein was overexpressed in E. coli and the recombinant protein was purified to apparent homogeneity by taking advantage of the thermosolubility of the protein and by using conventional column chromatography techniques

SNCA, NACP, PARK1, PARK4, PD1, α-synuclein Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Parkinson disease 4, autosomal dominant Lewy body

1mg/ml (determined by BCA assay)

Liquid in. 20mM Tris-HCl buffer (pH 7.5) containing 0.1M NaCl

Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Polymeropoulos MH., et al. (1997) Science. 276, 2045-7.;; Park, SM. et al. (2002) Blood. 100(7),2506-2514

> 95% by SDS-PAGE

SDS-PAGE

Human

Neuroscience

14.4 kDa (140aa) confirmed by MALDI-TOF (Molecular weight on SDS-PAGE will appear higher)

MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVTTVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA

Non-Tagged

E.coli

Recombinant Protein

P37840

a-Synuclein (A53T), SNCA, NACP, PARK1, alpha-Synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Alpha synuclein, Alpha-synuclein isoform NACP140, alphaSYN, MGC105443, MGC110988, MGC127560, MGC64356, Non A beta component of AD amyloid, Non A4 component of amyloid precursor, Non-A-beta component of alzheimers disease amyloid, precursor of PARK 1, PARK 4, PARK4, Parkinson disease familial 1, PD 1, PD1, Synuclein alpha,SNA2002-10ug,SNA2002-20ug,SNA2002-50ug,SNA2002-100ug,SNA2002-250ug,SNA2002-500ug,SNA2002-1mg,SNA2002-10,SNA2002-20,SNA2002-50,SNA2002-100,SNA2002-250,SNA2002-500,SNA2002-1

Park JY, et al. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinsons disease. (Glia. 2008){https://pubmed.ncbi.nlm.nih.gov/18449945/};;Kim KS, et al. Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease. (J Biol Chem. 2012){https://pubmed.ncbi.nlm.nih.gov/22619171/};;Konno M, et al. Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. (Mol Neurodegener. 2012){https://pubmed.ncbi.nlm.nih.gov/22892036/}